{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:40:50Z","timestamp":1793814050065,"version":"4.6.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00259-025-07613-4","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:28:23Z","timestamp":1762734503000},"page":"2257-2270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["[177Lu]Lu-PSMA SPECT\/CT for early response assessment using quantitative RECIP 1.0"],"prefix":"10.1007","volume":"53","author":[{"given":"Mutaz","family":"Kassas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Devriendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Guiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementine","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Danieli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loubna","family":"Taraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Kristanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Karfis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Woff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Flamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6421-0064","authenticated-orcid":false,"given":"Carlos","family":"Artigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"12","key":"7613_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"10459","key":"7613_CR2","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227\u201339.","journal-title":"Lancet"},{"issue":"11","key":"7613_CR3","first-page":"1651","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, et al. Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;63(11):1651\u20138.","journal-title":"J Nucl Med"},{"issue":"5","key":"7613_CR4","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1007\/s00259-021-05594-8","volume":"49","author":"F Rosar","year":"2022","unstructured":"Rosar F, Wenner F, Khreish F, Dewes S, Wagenpfeil G, Hoffmann MA, et al. Early molecular imaging response assessment based on determination of total viable tumor burden in [(68)Ga]Ga-PSMA-11 PET\/CT independently predicts overall survival in [(177)Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2022;49(5):1584\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7613_CR5","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2967\/jnumed.123.265874","volume":"64","author":"QA Shagera","year":"2023","unstructured":"Shagera QA, Karfis I, Kristanto P, Spyridon S, Diamand R, Santapau A, et al. PSMA PET\/CT for response assessment and overall survival prediction in patients with metastatic castration-resistant prostate cancer treated with androgen receptor pathway inhibitors. J Nucl Med. 2023;64(12):1869\u201375.","journal-title":"J Nucl Med"},{"issue":"11","key":"7613_CR6","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2967\/jnumed.121.263159","volume":"62","author":"J Calais","year":"2021","unstructured":"Calais J, Czernin J. PSMA expression assessed by PET imaging is a required biomarker for selecting patients for any PSMA-targeted therapy. J Nucl Med. 2021;62(11):1489\u201391.","journal-title":"J Nucl Med"},{"key":"7613_CR7","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2019.ed87","volume":"13","author":"HC Verduzco-Aguirre","year":"2019","unstructured":"Verduzco-Aguirre HC, Lopes G, Soto-Perez-De-Celis E. Implementation of diagnostic resources for cancer in developing countries: a focus on PET\/CT. Ecancermedicalscience. 2019;13:ed87.","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"7613_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00259-020-05038-9","volume":"48","author":"M Konijnenberg","year":"2021","unstructured":"Konijnenberg M, Herrmann K, Kobe C, Verburg F, Hindorf C, Hustinx R, et al. EANM position paper on article 56 of the Council directive 2013\/59\/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2021;48(1):67\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7613_CR9","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.2967\/jnumed.122.264770","volume":"64","author":"M Straub","year":"2023","unstructured":"Straub M, Kupferschl\u00e4ger J, Serna Higuita LM, Weissinger M, Dittmann H, la Foug\u00e8re C, et al. Dual-time-point posttherapy177Lu-PSMA-617 SPECT\/CT describes the uptake kinetics of mCRPC lesions and prognosticates patients\u2019 outcome. J Nucl Med. 2023;64(9):1431.","journal-title":"J Nucl Med"},{"issue":"1","key":"7613_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12880-025-01571-x","volume":"25","author":"TO Alkahtani","year":"2025","unstructured":"Alkahtani TO. Investigating the significance of SPECT\/CT-SUV for monitoring (177)Lu-PSMA-targeted radionuclide therapy: a systematic review. BMC Med Imaging. 2025;25(1):28.","journal-title":"BMC Med Imaging"},{"issue":"12","key":"7613_CR11","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for Castration-Resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402\u201318.","journal-title":"J Clin Oncol"},{"issue":"3","key":"7613_CR12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2967\/jnumed.122.264677","volume":"64","author":"N John","year":"2023","unstructured":"John N, Pathmanandavel S, Crumbaker M, Counter W, Ho B, Yam AO, et al. 177Lu-PSMA spect quantitation at 6 weeks (Dose 2) predicts short progression-free survival for patients undergoing 177Lu-PSMA-I&T therapy. J Nucl Med. 2023;64(3):410.","journal-title":"J Nucl Med"},{"issue":"2","key":"7613_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2967\/jnumed.122.264398","volume":"64","author":"S Pathmanandavel","year":"2023","unstructured":"Pathmanandavel S, Crumbaker M, Ho B, Yam AO, Wilson P, Niman R, et al. Evaluation of (177)Lu-PSMA-617 SPECT\/CT quantitation as a response biomarker within a prospective (177)Lu-PSMA-617 and NOX66 combination trial (LuPIN). J Nucl Med. 2023;64(2):221\u20136.","journal-title":"J Nucl Med"},{"issue":"4","key":"7613_CR14","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00259-023-06536-2","volume":"51","author":"MC Neubauer","year":"2024","unstructured":"Neubauer MC, Nicolas GP, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, et al. Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT\/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. Eur J Nucl Med Mol Imaging. 2024;51(4):1185\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7613_CR15","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1007\/s00259-024-06718-6","volume":"51","author":"H Song","year":"2024","unstructured":"Song H, Leonio MI, Ferri V, Duan H, Aparici CM, Davidzon G, et al. Same-day post-therapy imaging with a new generation whole-body digital SPECT\/CT in assessing treatment response to [(177)Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2024;51(9):2784\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7613_CR16","first-page":"1945","volume":"65","author":"RA Demirci","year":"2024","unstructured":"Demirci RA, Gulati R, Hawley JE, Yezefski T, Haffner MC, Cheng HH, et al. SPECT\/CT in early response assessment of patients with metastatic Castration-Resistant prostate cancer receiving (177)Lu-PSMA-617. J Nucl Med. 2024;65(12):1945\u201351.","journal-title":"J Nucl Med"},{"key":"7613_CR17","doi-asserted-by":"crossref","unstructured":"Unterrainer LM, De Leiris N, Unterrainer M, Delker A, Hempel L, Ells Z et al. Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data. Journal of Nuclear Medicine. 2025:jnumed.124.269431.","DOI":"10.2967\/jnumed.124.269431"},{"key":"7613_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164193","author":"N Mader","year":"2021","unstructured":"Mader N, Groener D, Tselis N, Banek S, Nagarajah J, Gr\u00fcnwald F, et al. Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13164193.","journal-title":"Cancers"},{"issue":"10","key":"7613_CR19","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.2967\/jnumed.119.240242","volume":"61","author":"A Gafita","year":"2020","unstructured":"Gafita A, Heck MM, Rauscher I, Tauber R, Cala L, Franz C, et al. Early prostate-specific antigen changes and clinical outcome after (177)Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61(10):1476\u201383.","journal-title":"J Nucl Med"},{"issue":"1","key":"7613_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29634-5","volume":"13","author":"Y Hakozaki","year":"2023","unstructured":"Hakozaki Y, Yamada Y, Takeshima Y, Taguchi S, Kawai T, Nakamura M, et al. Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients. Sci Rep. 2023;13(1):2672.","journal-title":"Sci Rep"},{"issue":"6 Pt 1","key":"7613_CR21","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1097\/01.ju.0000147771.92104.83","volume":"172","author":"TM Beer","year":"2004","unstructured":"Beer TM, Tangen CM, Bland LB, Thompson IM, Crawford ED. Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest oncology group study 8894. J Urol. 2004;172(6 Pt 1):2213\u20137.","journal-title":"J Urol"},{"issue":"12","key":"7613_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0307826","volume":"19","author":"T Zhang","year":"2024","unstructured":"Zhang T, Li W, Wei H, Huang Z, Yang J, Zeng H, et al. Prognostic value of baseline alkaline phosphatase of 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. PLoS ONE. 2024;19(12):e0307826.","journal-title":"PLoS ONE"},{"issue":"12","key":"7613_CR23","first-page":"1932","volume":"65","author":"M Muniz","year":"2024","unstructured":"Muniz M, Sartor O, Orme JJ, Koch RM, Rosenow HR, Mahmoud AM, et al. Outcomes for patients with metastatic Castration-Resistant prostate cancer and liver metastasis receiving [(177)Lu]Lu-PSMA-617. J Nucl Med. 2024;65(12):1932\u20138.","journal-title":"J Nucl Med"},{"issue":"4","key":"7613_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153981","volume":"11","author":"L Tang","year":"2016","unstructured":"Tang L, Li X, Wang B, Luo G, Gu L, Chen L, et al. Prognostic value of neutrophil-to-lymphocyte ratio in localized and advanced prostate cancer: a systematic review and meta-analysis. PLoS ONE. 2016;11(4):e0153981.","journal-title":"PLoS ONE"},{"key":"7613_CR25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267955","author":"S Yadav","year":"2024","unstructured":"Yadav S, Lowery B, Tuchayi AM, Jiang F, Saelee R, Aggarwal RR, et al. Impact of posttreatment SPECT\/CT on patient management during 177Lu-PSMA-617 radiopharmaceutical therapy. J Nucl Med. 2024. https:\/\/doi.org\/10.2967\/jnumed.124.267955.","journal-title":"J Nucl Med"},{"issue":"12","key":"7613_CR26","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1007\/s00259-023-06332-y","volume":"50","author":"A Holzgreve","year":"2023","unstructured":"Holzgreve A, Unterrainer M, Calais J, Adams T, Oprea-Lager DE, Goffin K, et al. Is PSMA PET\/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the ProPSMA trial. Eur J Nucl Med Mol Imaging. 2023;50(12):3750\u20134.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7613_CR27","doi-asserted-by":"crossref","unstructured":"Swiha M, Pathmanandavel S, Papa N, Sabahi Z, Li S, Zheng A et al. Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT\/CT and Pretherapy PSMA PET\/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. 2024:jnumed.124.267606.","DOI":"10.2967\/jnumed.124.267606"},{"key":"7613_CR28","doi-asserted-by":"crossref","unstructured":"Zaragori T, Chevalier E, Citerne Q, Roch V, Hossu G, Marie P-Y et al. Assessment of [Lu]Lu-DOTATATE Dosimetry from High-Speed Whole-Body Recordings Provided by a 360\u00b0 Cadmium\u2013Zinc\u2013Telluride Camera Compared with Results from a Conventional Anger-Camera Protocol. Journal of Nuclear Medicine. 2025:jnumed.124.268910.","DOI":"10.2967\/jnumed.124.268910"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07613-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07613-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07613-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:38:49Z","timestamp":1771479529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07613-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7613"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07613-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the ethics committee of Institut Jules Bordet (CE 3943) and conducted in accordance with the principles of the 1964 Declaration of Helsinki and its later amendments. Written informed consent was waived due to the retrospective study design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}